Eli Lilly and Company has announced that the FDA has approved Cymbalta for the management of fibromyalgia, a chronic widespread pain disorder.
Eli Lilly’s Cymbalta is said to be the first serotonin-norepinephrine reuptake inhibitor with proven efficacy for reducing pain in patients with fibromyalgia. The fibromyalgia indication represents the second FDA-approved use for Cymbalta for a pain disorder, demonstrating the medication’s analgesic effect.
The approval marks the fourth disorder that the FDA has approved for Cymbalta. In addition to fibromyalgia, Cymbalta is approved for the management of diabetic peripheral neuropathic pain and the treatment of major depressive disorder and generalized anxiety disorder, all in adults of age 18 years and older.
Madelaine Wohlreich, medical advisor and research physician at Lilly, said: “The approval of Cymbalta is important because it provides physicians and patients with a new treatment option shown to help reduce pain and improve functioning in this difficult-to-treat disorder.”
Comments